Find Academic Supervisors

• Laboratory Healthcare Delivery
• Clinical Biochemistry
• Endocrinology
• +3 more

Rousseau Gama is a Professor of Laboratory and Metabolic Medicine at the University of Wolverhampton's School of Medicine and Clinical Practice, with a focus on improving patient safety through laboratory healthcare delivery. He also serves as a Consultant Chemical Pathologist with Black Country Pathology Services at The Royal Wolverhampton NHS Trust. BSc in Biochemistry (University of Liverpool) MB ChB (University of Liverpool) MSc in Clinical Biochemistry (University of Surrey) MD (Chemical Pathology) (University of Liverpool) His research interests center on optimizing clinical pathways, diagnostic accuracy, and biochemical monitoring for endocrine and metabolic disorders. Key areas include EDTA contamination mitigation, vitamin B12 deficiency, and adrenal/glucose metabolism diagnostics. Recent publications emphasize clinical biochemistry , endocrinology , and diagnostic improvement , with subfields like EDTA interference , testosterone dynamics , and bile acid metabolism . His work often addresses analytical challenges in laboratory diagnostics. Rousseau has received grants for research on fecal biomarkers in pregnancy and inflammatory bowel disease, notably Fecal biomarkers in pregnancy and IBD (2015–2019). He has held leadership roles in editorial boards (Journal of Clinical Pathology, Journal of Laboratory and Precision Medicine) and professional committees (Association of Clinical Pathologists). As an educator, he teaches and examines undergraduate/postgraduate biomedical science modules and has led medical training programs in chemical pathology. His extensive publications (>150) reflect expertise in laboratory medicine and metabolic disorders.

• Neuroscience
• Hydrocephalus
• Neuroimmunology
• +4 more

Jaleel Miyan is a Senior Lecturer in Neuroscience at the University of Manchester's Faculty of Biology, Medicine and Health. He holds a PhD in Neurobiology from the University of Glasgow (1982) and a BSc in Biological Sciences from the University of Sussex (1978). He has held a Royal Society University Research Fellowship (1986–1996) and is a Fellow of the Royal Microscopical Society and the Higher Education Academy. He serves as a Visiting Professor at the Institute of Child Health, Lahore. His research focuses on the relationship between neural and immune systems, mechanisms underlying fetal hydrocephalus, and CSF's role in neurodevelopment. He discovered that folate supplementation can prevent fetal hydrocephalus and is advancing clinical trials for this treatment. His work contributes to UN SDGs related to health and education. He has published over 110 articles, including studies on CSF's role in neurodevelopment, folate metabolism in Parkinson's disease, and CSF metabolic errors in neuropsychiatric disorders. Awards include the Casey Holter Essay Prize and an Innovations in Teaching award for problem-based learning. Current projects include Autism@Manchester and research on brain disorders. He actively participates in conferences and has external roles with the Royal Society of Biology and Pakistan's Children's Hospital Lahore.

• Clinical Sciences
• Neurosciences
• Cardiorespiratory Medicine and Haematology
• +3 more

Dr. David Owen is a Clinical Professor in Molecular Pharmacology and Experimental Medicine at Imperial College London’s Department of Brain Sciences (Faculty of Medicine). He leads the Clinical Studies division at the NIHR Imperial Clinical Research Facility, which bridges laboratory discoveries to clinical treatments. His research focuses on the mitochondrial 18kDa Translocator Protein (TSPO), exploring its roles in neurodegenerative diseases (e.g., MS, Alzheimer’s) and pulmonary vascular disorders. He also contributes to medical education via Pharmacology teaching at the Imperial Medical School and directs the MRES in Clinical Research program. Key affiliations include the Centre for Advanced Therapeutics, Immuno-Pathology Network, and Section of Neurology. He chairs critical committees: North West London Integrated Formulary (2.6M patients) and Subregional IVIG stewardship across 6 NHS Trusts. His work integrates clinical practice (20% time in acute medicine) with translational research, emphasizing TSPO as a potential drug target and imaging biomarker. Research interests span neuroinflammation, imaging technologies (PET, MRI), and therapeutic development. Recent work includes WAND multi-modal brain datasets, MS pathology analyses, and TSPO’s role in microglial biology. He collaborates on open-source neuroimaging tools like the Welsh Advanced Neuroimaging Database.

• Structural Biology
• Biochemistry
• Microbiology
• +7 more

Dr. Arnaud Basle is a Researcher at Newcastle University , specializing in structural biology and biochemistry. His work focuses on bacterial physiology, glycan metabolism, and metal homeostasis, with a particular emphasis on enzyme mechanisms and protein structure-function relationships. Research Themes : Structural analysis of bacterial enzymes (e.g., polysaccharide lyases, glycoside hydrolases), copper transport systems, and outer membrane protein complexes. Collaborations : Professor Bert van den Berg, Dr. Alan Cartmell, Professor Harry Gilbert (Emeritus), and Dr. Jon Marles-Wright. Recent Trends : Studies on glycan uptake systems in gut Bacteroidetes, thermostable biocatalysts, and ribosome hibernation factors.

Nils Henrik HalbergView profile

Professor

• Cancer Metabolism
• Obesity and Cancer
• Metastatic Colonization
• +7 more

Nils Henrik Halberg is a Professor and NCMM Young Associate Investigator at the Department of Biomedicine, University of Bergen. His research focuses on the mechanistic links between obesity and cancer, particularly in breast and pancreatic cancers. Education: Graduate Studies: University of Copenhagen (completed 2009) Postdoctoral Training: UT Southwestern Medical Center (Dr. Philipp Scherer), Rockefeller University (Dr. Sohail Tavazoie) Halberg's research investigates how metabolic alterations in obesity promote cancer development and metastasis. His lab employs in vitro and in vivo cancer models, metabolic analysis, molecular biology, and clinical bioinformatics to study metastatic colonization and tumor microenvironment interactions. Key areas include hypoxia, fibrosis, and epigenetic regulation in obese adipose tissue and their impact on cancer progression. The 15 most recent publications reflect a consistent focus on obesity-cancer interactions, using advanced techniques like spatial transcriptomics, high-dimensional immune profiling, and metabolic pathway analysis. Themes include epigenetic memory of obesity, one-carbon metabolism, KRAS signaling, and immune modulation in cancer. The research spans breast, pancreatic, and lung cancers, emphasizing metabolic reprogramming and tumor-stroma crosstalk. Scientific Awards: No specific awards mentioned in the text. Advising and Grants: Halberg supervises multiple graduate students, as evidenced by numerous master’s theses and doctoral dissertations under his guidance. His lab is actively funded, enabling the operation of a research group conducting systemic studies on cancer metabolism and metastasis. He teaches BMED331 and BMED381 at the University of Bergen. Labs and Teams: He leads the Halberg Group, which is part of the 'Metabolism and Cancer' and 'Cellular Networks' research groups at the Department of Biomedicine. The lab maintains a website and is affiliated with the Centre for Cancer Biomarkers (CCBIO) or similar networks, indicated by the NCMM (Norwegian Centre for Molecular Medicine) Young Associate Investigator title.

Winfried SiffertView profile

Professor

• Pharmacogenetics
• Clinical Pharmacology
• Genetic Epidemiology
• +12 more

Prof. Dr. Winfried Siffert is a faculty member at the Medical Faculty of the University of Duisburg-Essen, where he leads the Institute of Pharmacogenetics at the University Hospital Essen. His work integrates research, clinical diagnostics, and teaching in pharmacogenetics and clinical pharmacology. His research focuses on genetic variants influencing disease susceptibility and drug response , particularly in cancer, cardiovascular disorders, and immune-related conditions. Key areas include polymorphisms in G proteins , BCL2 , MTHFR , and GNAS , with implications for personalized therapy and adverse drug reaction prediction. His lab is ISO 9001:2015 certified and provides diagnostic genetic testing for drug metabolism genes such as NAT2 , CYP2C19 , CYP2C9 , ApoE , DPYD , and UGT1A1 . The recent publications reflect a strong trend in cancer pharmacogenetics and genetic biomarkers for disease progression , especially in hematologic malignancies. His work bridges molecular genetics with clinical application, contributing significantly to evidence-based pharmacogenomic testing. Prof. Siffert is actively involved in academic teaching, representing the subject of Clinical Pharmacology, and oversees a high-volume diagnostic service integrated into hospital workflows via the medico system. His institute plays a key role in implementing pharmacogenetic testing prior to drug therapies such as lecanemab, mavacamten, and fluoropyrimidines, in line with regulatory recommendations. He leads the Institute of Pharmacogenetics, which operates within the Medical Research Center at the University Hospital Essen, combining research innovation with routine diagnostics and educational outreach.

• Social Deprivation Studies
• Heritage Culture Institutionalization
• Climate Socialities
• +4 more

Aet Annist is an Associate Professor of Ethnology at the University of Tartu's Institute of Cultural Studies. Her research focuses on deprivation (social, symbolic, ethnic, and future deprivation), new class relations, and the institutionalization of heritage culture. She has contributed to projects such as the IUT initiative led by UNESCO Chairholder Professor Kuutma and the University of Manchester's PROMISE project. Her work intersects with climate socialities, forest protests, and heritage culture connections. Annist is actively engaged with Estonian media, governmental advisory roles, and activist collaborations in environmental and social justice movements. Education: Holds a PhD in Ethnology. Supervised multiple master's and doctoral theses, including works on climate activism, diaspora communities, and transnational nationalism. Research Interests: Explores how peripheral regions' heritage institutions shape socio-cultural dynamics. Current projects address climate change impacts on community structures and the sociopolitical dimensions of environmental protests. Her interdisciplinary approach bridges ethnology, sociology, and environmental studies. Awards: None explicitly listed. Grants & Funding: Involved in EU-funded and cross-institutional projects such as IUT and PROMISE. Engaged in applied research with Estonian ministries and the Riigikogu. Labs/Teams: Part of the UNESCO Chair in Applied Studies of the Intangible Cultural Heritage and collaborates with international academic networks.

• Plant Biology
• Biofortification
• Molecular Biology
• +4 more

Dominique Van Der Straeten is a Professor at Ghent University , specializing in plant biology, biofortification, and hormone signaling. Her research bridges molecular mechanisms with agricultural applications, focusing on ethylene, auxin, and cytokinin interactions. Key Research Areas: Biofortification, Ethylene Signaling, Vitamin Biosynthesis, Stress Physiology, Agricultural Biotechnology Institutional Affiliation: Ghent University (UGent), Department of Plant Sciences Her work includes 15 recent publications on topics like folate/thiamin metabolism in Arabidopsis and rice, UV-B phototropism, and plant-microbe interactions. She mentors PhD candidates such as Maria Vicente Faustino and Lucas Vanhaelewyn . Scientific Trends in her articles include: Elucidating plant hormone crosstalk (ethylene, auxin, cytokinin) Advancing biofortification strategies for B-vitamins Decoding stress responses in crops under climate change Developing analytical methods for metabolite quantification

Anya ArthursView profile

Research Fellow

• Molecular Biology
• Cell Biology
• Placental Development
• +6 more

Dr. Anya Arthurs is a Research Fellow in Cell and Molecular Biology at Flinders University's College of Medicine and Public Health and Full Member of the Flinders Health and Medical Research Institute. She holds a PhD from the University of Newcastle (2019) and has established herself as a leading researcher in placental biology and non-coding RNA mechanisms. Her educational background includes a PhD in Medical Biochemistry from the University of Newcastle (2016-2019), a Bachelor of Biomedical Science (Honours Class I) from the University of Newcastle (2015-2016), and a Bachelor of Science in Pharmacology from the University of Sydney (2011-2014). Dr. Arthurs specializes in the molecular and cell biology of the placenta, with particular focus on how non-coding RNAs influence human development and disease, especially in reproductive health and placental ageing. Her technical expertise centers on generating patient-derived, genetically edited placental organoids—complex in vitro models that simulate development and disease processes. Her research aims to elucidate fundamental biological mechanisms while developing diagnostic tools to inform clinical decision-making and identify novel drug targets. Her recent publications demonstrate a strong focus on placental organoid technology, non-coding RNA function in placental development, folate metabolism's impact on pregnancy outcomes, and computational tools for microRNA analysis. These works span molecular biology, reproductive medicine, nutritional science, and bioinformatics, reflecting her interdisciplinary approach to understanding pregnancy complications and placental function. 2025 Future Making Fellowship, University of Adelaide ($499,000) 2025 NHMRC Ideas Grant ($1.17M) 2025 Society for Reproductive Biology Career Development Award ($5,000) 2020 HDA Schools Communicator Award 2019 Ross Wishart Memorial Award Multiple grants from Channel 7 Children's Research Foundation, MRFF, and Robinson Research Institute Dr. Arthurs has secured substantial research funding totaling over $1.7 million in the past two years alone, including major grants from NHMRC and MRFF. Her work has been featured in prominent media outlets including Channel 7 News, The Conversation, and LiveScience.com. She maintains active collaborations with researchers across Australia and internationally, particularly in the areas of placental development and pregnancy complications. Her patient-derived placental organoid models represent cutting-edge methodology in reproductive biology research, offering new insights into pregnancy health and potential therapeutic interventions.

Po-Wah SoView profile

Associate Professor

• Neuroscience
• Neurodegenerative Diseases
• Biomedical Imaging
• +3 more

Dr. Po-Wah So is a Reader in Biomedical Imaging and Spectroscopy at King's College London, affiliated with the School of Neuroscience and Department of Neuroimaging. Her research focuses on brain aging, neurodegenerative diseases (e.g., Alzheimer's), and the role of metals like iron in neurological processes. She employs advanced MRI and NMR techniques to study metabolic diseases and their interactions with brain health. Dr. So holds a PhD in Chemistry from Birkbeck, University of London, and has extensive academic and industry experience in NMR applications. Her work includes pioneering synchrotron-based metallomics mapping and collaborations on translational imaging projects. She has led or co-led multiple grants from bodies like Alzheimer's Research UK and the Wellcome Trust, focusing on iron metabolism, metabolic syndrome, and pediatric neuroimaging. Dr. So also contributes to academic leadership as Departmental Admissions Tutor and module leader in neuroscience and bioimaging programs.

Merrill EliasView profile

Professor

• Cardiovascular Epidemiology
• Cognitive Aging
• Neuropsychology
• +7 more

Merrill Elias is a Professor of Psychology at the University of Maine and a cooperating professor in the Graduate School of Biomedical Science and Engineering (GSBSE). He has been a key figure in cardiovascular epidemiology and cognitive aging research since joining the university in 1977. His work is deeply connected to the Maine-Syracuse Longitudinal Study (MSLS), a long-term community-based investigation into cardiovascular and cognitive health. Ph.D., Experimental Psychology, Purdue University (1963) MPH, Epidemiology and Biostatistics, Boston University School of Public Health (1996) Post-doctoral Training, Duke University Center for Aging and Human Development (1971) B.A., Allegheny College (1960) Dr. Elias's research focuses on the interplay between cardiovascular risk factors and cognitive performance across the lifespan. His work explores how variables such as blood pressure, arterial stiffness, diabetes, diet (e.g., Mediterranean diet, chocolate), vitamins (B12, B6, folate), and lifestyle factors influence brain health. The MSLS provides a rich dataset for examining these relationships longitudinally. The 15 most recent publications highlight a consistent focus on hypertension, diet-cognition links, and vascular contributions to cognitive decline. His work spans clinical measurement accuracy, nutritional epidemiology, and neuroepidemiology, often using data from the MSLS. Themes include dietary patterns, blood pressure screening practices, and vascular biomarkers as predictors of cognitive outcomes. Scientific honors include: Fellow, American Psychological Association Fellow, Society of Psychosomatic Medicine Fellow, American Heart Association Councils on High Blood Pressure and Epidemiology Dr. Elias has secured sustained research funding from the National Institutes of Health (NIA, NHLBI), National Science Foundation (NSF), and NATO. He mentors students through the GSBSE and the MSLS, fostering interdisciplinary research. His collaborations span institutions such as Boston University, Oxford University, University of Southern California, and Australian National University. He directs the Laboratory of Cardiovascular Epidemiology, Aging and Neuropsychology, which continues to produce impactful research on aging, cognition, and cardiovascular health.

Wei GaoView profile

Assistant Professor

• Nanomedicine
• Cancer Immunotherapy
• Immunomodulation
• +5 more

Wei Gao is an Assistant Professor of Pharmacology at the University of Houston College of Pharmacy, specializing in the Department of Pharmacological and Pharmaceutical Sciences. With a focus on nanomedicine and immunotherapy, Dr. Gao develops innovative strategies to modulate B cells and myeloid cells for treating cancer and immune diseases. B.S., School of Life Science and Technology, China Pharmaceutical University Master, School of Pharmacy, University of Calabria, Italy M.S. in Pharmaceutics, China Pharmaceutical University Ph.D. in Pharmaceutics, Peking University Health Science Center Postdoctoral Research Fellow (2017-2021) and Assistant Research Scientist (2022-2024), University of Michigan College of Pharmacy Dr. Gao’s research emphasizes nanovaccine development and overcoming STING pathway resistance in pancreatic cancer through regulatory B cell elimination. His work also explores albumin-based nanoformulations for lymphatic system targeting. Recent publications highlight advancements in tumor microenvironment-responsive nanoparticles, multidrug resistance reversal, and combinatorial immunotherapy strategies. Dr. Gao is a co-investigator on the NIH R01 CA285790-01 grant (2024-2029) and a member of the American Association for Cancer Research, Controlled Release Society, American Association of Pharmaceutical Scientists, and Society for Immunotherapy of Cancer.

Julie St-PierreView profile

Professor

• Mitochondria
• Metabolism
• Metabolomics
• +3 more

Dr. Julie St-Pierre is a Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa Faculty of Medicine. Her research focuses on mitochondrial metabolism, cancer biology, and metabolic reprogramming, particularly in breast cancer progression. She previously served as Director of the Metabolomics Core Facility at McGill University (2009-2017) and has held appointments as Assistant and Associate Professor at McGill (2008-2017). BSc, Université Laval MSc, Université Laval PhD, Cambridge University, UK The St-Pierre laboratory investigates how mitochondrial functions contribute to energy homeostasis in physiological and pathological conditions. Key projects examine PGC-1s' roles in cancer metastasis, therapeutic resistance, and metabolic dependencies, using real-time bioenergetics measurements, metabolomics, and transcription profiling. Her team collaborates internationally to advance understanding of metabolic adaptations in disease. Her recent publications highlight metabolic drug sensitivity, mitochondrial regulation of cancer progression, and cross-talk between metabolic pathways and cellular stress responses. The laboratory's work spans cancer biology, metabolic diseases, and neurodegeneration, with methodological emphasis on systems-level metabolomics. Dr. St-Pierre's lab operates in Roger Guindon Hall, Room 4510B (office) and 4210 (lab), and can be reached at julie.st-pierre@uOttawa.ca.

Xiaojian ShaoView profile

Adjunct Professor

• Bioinformatics
• Computational Biology
• Epigenomics
• +4 more

Dr. Xiaojian Shao is an Adjunct Professor at the Department of Biochemistry, Microbiology and Immunology of the Faculty of Medicine, University of Ottawa, and a Research Officer at the Digital Technologies Research Center, National Research Council of Canada. His research focuses on Bioinformatics, Computational Biology, and Epigenomics , with expertise in Single Cell Genomics, Machine Learning, and Cell/Gene Therapy. University: University of Ottawa School: Faculty of Medicine Department: Department of Biochemistry, Microbiology and Immunology Academic Rank: Adjunct Professor Other Role: Research Officer, NRC Digital Technologies Research Center Emails: xiaojian.shao@nrc-cnrc.gc.ca, xshao2@uOttawa.ca Dr. Shao’s research spans epigenetic mechanisms in diseases, environmental impacts on methylomes, and computational methods for genomic analysis. His work includes: Cross-sectional studies on DDT/DDE exposure and sperm epigenome DNAmethylation changes in rheumatoid arthritis and dementia Development of software tools like DMEAS for methylation analysis Investigations into growth hormone effects and folate metabolism Single-cell sequencing applications in COPD and cancer Recent publications highlight trends in environmental epigenetics, disease biomarkers, and computational methods , including cross-continental studies on toxicology and neurodegenerative diseases. Dr. Shao collaborates with institutions such as the National Research Council of Canada and contributes to journals like Environmental Health Perspectives and Communications Biology .

• Hematology
• Cardiovascular Medicine
• Proteomics
• +2 more

Anders Henriksson is an Adjunct Professor at Mid Sweden University in the Department of Natural Sciences, Design and Sustainable Development (NDH). His research focuses on hematological and cardiovascular disorders, particularly in the context of abdominal aortic aneurysm pathophysiology, biomarker discovery, and transfusion medicine. Academic Rank: Adjunct Professor Department: Department of Natural Sciences, Design and Sustainable Development (NDH) Email: anders.henriksson@miun.se Location: Sundsvall, Sweden Henriksson's research spans proteomic analysis of vascular diseases, blood group immunology in infectious response, and exercise-induced physiological changes. He has extensively studied abdominal aortic aneurysm biomarkers and coagulation dynamics in trauma and surgical settings. Recent publications highlight his work on proteomic approaches for circulating biomarkers (2015-2025), blood group impacts on viral immunity (2025), and coagulation anomalies in aneurysm patients (2012-2022). His studies often involve multidisciplinary collaborations with clinical and laboratory science teams. Henriksson has contributed to understanding seasonal variations in biomarkers (2016), transfusion practices in vascular surgery (2013), and athlete-specific hematological changes (2020). His proteomic research (2018-2022) demonstrates sustained focus on molecular diagnostics for cardiovascular conditions.